Evaluation the Efficacy of Zinc on Botulinum Toxin A Injection

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorTishreen University

About this trial

This clinical trial seeks to investigate a promising new approach to enhance the effectiveness and duration of Botulinum Toxin A (BTX-A) for the treatment of hyperactive masseter muscles. By investigating the role of oral zinc supplementation, this study could provide a cost-effective, sustainable solution for patients suffering from both aesthetic concerns and functional limitations associated with MMH and bruxism. The findings of this study will expand the clinical applications of BTX-A, offering longer-lasting relief and reducing the need for frequent injections, which could revolutionize the management of MMH in clinical practice.

Eligibility criteria

Qualifiers

None

Disqualifiers

Pregnancy or lactation;

Patients have aminoglycosides or vit B12.

Prior BTX-A treatment to the masseter within the previous 12 months;

Neuromuscular disorders or hypersensitivity to BTX-A or zinc compounds;

Trial design

Treatments tested in this trial

  • BOTOX 100U in normal saline with zinc
  • BOTOX 100U in normal saline with placebo

Treatment groups

20 Participants
are divided into 2 treatment groups

Sponsors and collaborators